TBB

TargetMol
Product Code: TAR-T2695
Supplier: TargetMol
CodeSizePrice
TAR-T2695-5mg5mg£102.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2695-1mL1 mL * 10 mM (in DMSO)£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2695-10mg10mg£114.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2695-25mg25mg£139.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2695-50mg50mg£201.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2695-100mg100mg£279.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2695-200mg200mg£403.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
TBB(NSC 231634) is a highly selective, ATP/GTP-competitive inhibitor of casein kinase-2 (CK2).
CAS:
17374-26-4
Formula:
C6HBr4N3
Molecular Weight:
434.711
Pathway:
PI3K/Akt/mTOR signaling; Metabolism; Cell Cycle/Checkpoint; Stem Cells
Purity:
0.9886
SMILES:
Brc1c(Br)c(Br)c2[nH]nnc2c1Br
Target:
GSK-3; Casein Kinase; CDK

References

1. De Moliner E, et al. Alternative binding modes of an inhibitor to two different kinases. Eur J Biochem. 2003 Aug;270(15):3174-81. 2. Orzechowska E, et al. Time schedule-dependent effect of the CK2 inhibitor TBB on PC-3 human prostate cancer cell viability. Oncol Rep. 2012 Jan;27(1):281-5. 3. Sarno S, et al. Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2'). FEBS Lett. 2001 May 4;496(1):44-8. 4. Ljubimov AV, et al. Involvement of protein kinase CK2 in angiogenesis and retinal neovascularization. Invest Ophthalmol Vis Sci. 2004 Dec;45(12):4583-91. 5. Wang C, De Su L, Shao Y M, et al. Involvement of PML-I in reformation of PML nuclear bodies in acute promyelocytic leukemia cells by leptomycin B[J]. Toxicology and applied pharmacology. 2019, 384: 114775. 6. Zhu S, Cheng X, Wang R, et al. Restoration of microRNA function impairs MYC-dependent maintenance of MLL leukemia[J]. Leukemia. 2020: 1-5.